Insider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Sells 3,777 Shares of Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith A. Goldan sold 3,777 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $58,543.50. Following the completion of the transaction, the chief financial officer now owns 90,746 shares in the company, valued at $1,406,563. This represents a 4.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ:SNDX traded down $0.15 during trading on Wednesday, reaching $14.86. 3,212,288 shares of the company’s stock traded hands, compared to its average volume of 2,342,525. Syndax Pharmaceuticals, Inc. has a 12 month low of $12.06 and a 12 month high of $25.34. The company has a 50 day moving average of $14.00 and a 200-day moving average of $17.27. The stock has a market capitalization of $1.27 billion, a P/E ratio of -4.09 and a beta of 0.90.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Bryce Point Capital LLC bought a new position in Syndax Pharmaceuticals in the 4th quarter worth about $417,000. Knott David M Jr grew its position in Syndax Pharmaceuticals by 4.8% in the 4th quarter. Knott David M Jr now owns 128,000 shares of the company’s stock worth $1,692,000 after purchasing an additional 5,856 shares during the last quarter. Trexquant Investment LP grew its position in Syndax Pharmaceuticals by 1,309.7% in the 4th quarter. Trexquant Investment LP now owns 471,292 shares of the company’s stock worth $6,230,000 after purchasing an additional 437,859 shares during the last quarter. DnB Asset Management AS grew its position in Syndax Pharmaceuticals by 32.1% in the 4th quarter. DnB Asset Management AS now owns 22,943 shares of the company’s stock worth $303,000 after purchasing an additional 5,581 shares during the last quarter. Finally, Simplify Asset Management Inc. grew its position in Syndax Pharmaceuticals by 20.8% in the 4th quarter. Simplify Asset Management Inc. now owns 147,641 shares of the company’s stock worth $1,952,000 after purchasing an additional 25,456 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. UBS Group assumed coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They issued a “buy” rating and a $37.00 target price for the company. Scotiabank dropped their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a research report on Thursday, November 21st. Citigroup boosted their target price on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, November 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $36.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).